-
Global Biotechnology & Pharmaceutical Markets2 days agoSecurity concerns in U.S., China reshaping biotech
BIOCENTURY | POLITICS, POLICY & LAWSECURITY CONCERNS IN U.S., CHINA RESHAPING BIOTECHPlus: Gilead’s $1.3B PepStar deal and Merck and Moderna’s melanoma vaccine
-
Global Biotechnology & Pharmaceutical Markets2 days agoSTAT+: Roche gets a lung cancer win with its KRAS drug divarasib
One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung cancer.
-
Global Biotechnology & Pharmaceutical Markets2 days agoWorld HUPO 2026: Asia-Pacific Ambition and the Road to Predictive Biology
Conversations at HUPO 2026 revolved around questions that reach beyond the proteomics community: who will develop disease, why treatment fails, and whether a computational model can...
-
Global Biotechnology & Pharmaceutical Markets3 days agoAustralia’s clinical trial advantage gains ground amid U.S. uncertainty
CROs cite faster startup timelines, regulatory predictability and tax incentives as reasons for growing interest in Australia. State investments in manufacturing, translational research and advanced therapies...
-
Global Biotechnology & Pharmaceutical Markets3 days agoNew Data on Lilly’s Investigational Treatment Olomorasib at ESMO 2026 Show Durable First-Line Activity in KRAS G12C-Mutant Non-Small Cell Lung Cancer
INDIANAPOLIS, Oct. 25, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new first-line data on olomorasib, its investigational, next-generation KRAS G12C inhibitor, at...
-
Global Biotechnology & Pharmaceutical Markets4 days agoSTAT+: At ESMO, AstraZeneca’s cancer pursuits get a showcase
AstraZeneca has seen major momentum in oncology in recent years. It got a big showcase at Europe's top cancer conference.
-
Global Biotechnology & Pharmaceutical Markets5 days agoSTAT+: The ESMO presentation everyone’s been waiting for
Moderna and Merck's 'presidential' presentation, and other news from Day 2 of the European Society for Medical Oncology meeting in Madrid.
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
STAT+: HHS moves to allow compounding of some unapproved peptides
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
